Bio Green Med Solution Inc (BGMS) Stock Price, Quote & News

Company Profile

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It also researches and develops pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry: Biotechnology

Sector: Healthcare

Phone: 60 9 08517 7330

Website: www.bgmsglobal.com

Address:

Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia

AlienRabbit Oct. 9 at 2:00 PM

$BGMS

0 · Reply

_www_larval_com_ Oct. 9 at 1:47 PM

$BGMS has turned 11% higher to -3% (~63Kv) a few minutes ago, follow for more volatility.

0 · Reply

Acclr8n Oct. 9 at 12:10 PM

$BGMS FINALLY!! We got this CYCC board changed to BGMS

0 · Reply

Acclr8n Oct. 8 at 10:05 AM

$BGMS $BGMS shorts are gonna be in a heap of trouble here soon. 0 shares available left to short and a CTB of almost 260%. They’ll be tasting their own blood when this makes a massive upside move

1 · Reply

Acclr8n Oct. 8 at 9:40 AM

$CYCC @Stocktwits please change CYCC to $BGMS, thanks!!

0 · Reply

Don_Frye Oct. 8 at 8:53 AM

$CYCC sold 2 days ago .. pfff

0 · Reply

Majid74 Oct. 7 at 9:59 PM

$CYCC

2 · Reply

TradingRunners Sep. 30 at 8:46 PM

Wow what is happening to MTEX right now!? Seems like ALL volume and momentum are shifting into MTEX!! Could it be the next crazy runner of the day?? Bulls should keep it on watch - MTEX is breaking out! Also watching: $DTREF $CYCC $AKAN $TLRY $IMCC x

0 · Reply

av069 Sep. 26 at 12:02 PM

$BGMS will this stock ever pull back ?

0 · Reply

Marau2021 Sep. 25 at 7:42 PM

$CYCC yup

0 · Reply

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Aug 4, 2025, 6:50 PM EDT - 2 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Jul 15, 2025, 12:17 PM EDT - 3 months ago

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Jul 7, 2025, 6:00 AM EDT - 3 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Jul 7, 2025, 6:00 AM EDT - 3 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Jul 2, 2025, 9:00 AM EDT - 3 months ago

Cyclacel Pharmaceuticals Announces Stock Split

Jun 20, 2025, 4:30 PM EDT - 3 months ago

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Jun 3, 2025, 4:15 PM EDT - 4 months ago

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

May 15, 2025, 12:50 AM EDT - 5 months ago

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 7, 2025, 9:00 AM EDT - 5 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

May 6, 2025, 6:00 AM EDT - 5 months ago

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

Apr 2, 2025, 4:05 PM EDT - 6 months ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Mar 24, 2025, 7:30 AM EDT - 7 months ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Feb 27, 2025, 1:38 PM EST - 8 months ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Jan 3, 2025, 9:01 AM EST - 9 months ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Dec 5, 2024, 4:05 PM EST - 10 months ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Nov 14, 2024, 4:15 PM EST - 11 months ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 11 months ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 12, 2024, 4:45 PM EST - 11 months ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Oct 24, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 23, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Sep 25, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Aug 14, 2024, 8:18 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Jun 26, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

May 14, 2024, 8:08 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 2, 2024, 4:30 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Mar 19, 2024, 6:09 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 6, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Feb 20, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Jan 30, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 8, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Dec 22, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 18, 2023, 9:00 AM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 12, 2023, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Nov 30, 2023, 9:15 AM EST - 2 years ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 28, 2023, 5:15 PM EST - 2 years ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 13, 2023, 7:32 PM EST - 2 years ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

AlienRabbit Oct. 9 at 2:00 PM

$BGMS

0 · Reply

_www_larval_com_ Oct. 9 at 1:47 PM

$BGMS has turned 11% higher to -3% (~63Kv) a few minutes ago, follow for more volatility.

0 · Reply

Acclr8n Oct. 9 at 12:10 PM

$BGMS FINALLY!! We got this CYCC board changed to BGMS

0 · Reply

Acclr8n Oct. 8 at 10:05 AM

$BGMS $BGMS shorts are gonna be in a heap of trouble here soon. 0 shares available left to short and a CTB of almost 260%. They’ll be tasting their own blood when this makes a massive upside move

1 · Reply

Acclr8n Oct. 8 at 9:40 AM

$CYCC @Stocktwits please change CYCC to $BGMS, thanks!!

0 · Reply

Don_Frye Oct. 8 at 8:53 AM

$CYCC sold 2 days ago .. pfff

0 · Reply

Majid74 Oct. 7 at 9:59 PM

$CYCC

2 · Reply

TradingRunners Sep. 30 at 8:46 PM

0 · Reply

av069 Sep. 26 at 12:02 PM

$BGMS will this stock ever pull back ?

0 · Reply

Marau2021 Sep. 25 at 7:42 PM

$CYCC yup

0 · Reply

TradeHuntFish Sep. 24 at 10:56 AM

XPON is still flying under the radar… But it’s sitting on a lithium battery business with real applications, a tiny float, and a chart base forming. Add in macro momentum + potential Trump-related energy hype and this could ignite. $DRUG $BGMS $SYBX $BNBX $SLNO

0 · Reply

UNCLEARTHUR Sep. 23 at 8:56 AM

$CYCC @Stocktwits Can you change to BGMS please. The name changed on 12/9/25 Thanks

0 · Reply

AliHervey720 Sep. 21 at 7:42 AM

$BGMS Biotech with phase II data. High risk speculation. Trading near cash value. No pattern.

0 · Reply

golftrader111 Sep. 17 at 11:18 PM

$CYCC what are we expecting to happen with this one anyone have any ideas ? Pretty deep in the bag

0 · Reply

Don_Frye Sep. 12 at 3:02 PM

$CYCC same shit different name

0 · Reply

Don_Frye Sep. 12 at 2:43 PM

$CYCC is BGMS now

0 · Reply

D_Young Sep. 12 at 12:02 PM

$BGMS As a result of the Exchange Transaction, the Company changed the ticker symbols for its common stock and preferred stock from CYCC and CYCCP, respectively, to BGMS and BGMSP, respectively. The Company’s securities will continue to trade on the Nasdaq. No action is required by the Company's stockholders with respect to the ticker symbol change. (From their press release.)

0 · Reply

Sw1ngb0t Sep. 12 at 11:47 AM

$BGMS the tradingview chart looks broken for this. no ticker change. weird

0 · Reply

Viacheslav45 Sep. 12 at 11:12 AM

$BGMS syper

0 · Reply

WallStreetBuyDip Sep. 10 at 2:21 PM

$BGMS Trading at $6.51, with average volume at 477,384, the stock seems quieter than usual compared to recent days.

0 · Reply

WallStreetBuyDip Sep. 10 at 1:50 PM

$BGMS Trading at $6.51, quite a bit off its highest at $343.20 and lowest at $3.31. Average volume stands at 477,354, very different from recent trading volumes.

0 · Reply

Don_Frye Sep. 10 at 8:37 AM

$BGMS make this company into a bitcoin treasury . i want to see 1000% gains in a single day

0 · Reply

Market Cap	10.57M
Revenue (ttm)	40,000.00
Net Income (ttm)	-11.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28,025.00%
Debt to Equity Ratio	0.00

Volume	506,083
Avg Vol	294,646
Day's Range	N/A - N/A
Shares Out	2.24M
Stochastic %K	72%
Beta	0.09
Analysts	Hold
Price Target	N/A